Cartesian Therapeutics, Inc. (RNAC) Net Income by Year
Cartesian Therapeutics, Inc. reported a net loss of $130.3M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $151.9M net loss. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters Cartesian Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
RNAC Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
RNAC Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Cartesian Therapeutics, Inc. financials
Frequently Asked Questions
What was Cartesian Therapeutics, Inc.'s net income in fiscal year 2025?
Cartesian Therapeutics, Inc. reported a net loss of $130.3M in fiscal year 2025.
How fast is Cartesian Therapeutics, Inc.'s net income growing?
Cartesian Therapeutics, Inc. (RNAC) reported a $77.4M net loss in fiscal year 2024 and a $130.3M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
What is Cartesian Therapeutics, Inc.'s net income over the last twelve months?
Cartesian Therapeutics, Inc. (RNAC) reported a $151.9M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Cartesian Therapeutics, Inc.'s net income changed over the years?
Across the 12 fiscal years this page covers, Cartesian Therapeutics, Inc. (RNAC) net income went from -$12.9M in fiscal year 2014 to -$130.3M in fiscal year 2025.
What was Cartesian Therapeutics, Inc.'s net income in the most recent quarter?
Cartesian Therapeutics, Inc. (RNAC) reported $15.8M in net income in Q2 2026. This represents a decrease of 0.7% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Cartesian Therapeutics, Inc. (RNAC) reported on that line in every period on record.